These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 23582779)

  • 1. Discovery of novel orally bioavailable GPR40 agonists.
    Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
    Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of the imidazole-derived GPR40 agonist AM-3189.
    Ma Z; Lin DC; Sharma R; Liu J; Zhu L; Li AR; Kohn T; Wang Y; Liu JJ; Bartberger MD; Medina JC; Zhuang R; Li F; Zhang J; Luo J; Wong S; Tonn GR; Houze JB
    Bioorg Med Chem Lett; 2016 Jan; 26(1):15-20. PubMed ID: 26620255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Pan M; Su X; Dai Y; Fu M; Cai X; Shi W; Huang W; Qian H
    Bioorg Med Chem; 2016 May; 24(9):1981-7. PubMed ID: 27020683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
    Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
    J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel potent GPR40 full agonist.
    Meegalla SK; Huang H; Martin T; Xu J; Zhao S; Liu J; Hall M; Gunnet J; Wang Y; Rady B; Silva J; Otieno M; Arnoult E; Paul Lee S; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):720-726. PubMed ID: 29366647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.
    Ye Z; Liu C; Zou F; Cai Y; Chen B; Zou Y; Mo J; Han T; Huang W; Qiu Q; Qian H
    Bioorg Med Chem; 2020 Jul; 28(13):115574. PubMed ID: 32546302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Updates on Free Fatty Acid Receptor 1 (GPR-40) Agonists for the Treatment of Type 2 Diabetes Mellitus.
    Rani L; Grewal AS; Sharma N; Singh S
    Mini Rev Med Chem; 2021; 21(4):426-470. PubMed ID: 33100202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists.
    Huang H; Winters MP; Meegalla SK; Arnoult E; Paul Lee S; Zhao S; Martin T; Rady B; Liu J; Towers M; Otieno M; Xu F; Lim HK; Silva J; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(3):429-436. PubMed ID: 29258772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
    Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus.
    Lizarzaburu M; Turcotte S; Du X; Duquette J; Fu A; Houze J; Li L; Liu J; Murakoshi M; Oda K; Okuyama R; Nara F; Reagan J; Yu M; Medina JC
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5942-7. PubMed ID: 22884988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.
    Duan H; Ning M; Zou Q; Ye Y; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2015 Apr; 58(8):3315-28. PubMed ID: 25710631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
    Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
    J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
    Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.